BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23774254)

  • 1. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease.
    Rodriguez-Perez AI; Dominguez-Meijide A; Lanciego JL; Guerra MJ; Labandeira-Garcia JL
    Neurobiol Dis; 2013 Oct; 58():209-19. PubMed ID: 23774254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors.
    Villar-Cheda B; Dominguez-Meijide A; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
    Neurobiol Dis; 2012 Aug; 47(2):268-79. PubMed ID: 22542954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease.
    Liu LX; Chen WF; Xie JX; Wong MS
    Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
    Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
    Garrido-Gil P; Joglar B; Rodriguez-Perez AI; Guerra MJ; Labandeira-Garcia JL
    J Neuroinflammation; 2012 Feb; 9():38. PubMed ID: 22356806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death.
    Borrajo A; Rodriguez-Perez AI; Villar-Cheda B; Guerra MJ; Labandeira-Garcia JL
    Neuropharmacology; 2014 Oct; 85():1-8. PubMed ID: 24878243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
    Quesada A; Micevych PE
    J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease.
    Al-Sweidi S; Morissette M; Bourque M; Di Paolo T
    Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of estrogen and levodopa in 1-methyl-4-pheny-l-1, 2, 3, 6-tetrahydropyridine (mptp)-induced cognitive deficit in Parkinsonian ovariectomized mice model: A comparative study.
    Yadav SK; Pandey S; Singh B
    J Chem Neuroanat; 2017 Nov; 85():50-59. PubMed ID: 28711564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
    Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
    J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
    Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
    Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β.
    Muñoz A; Garrido-Gil P; Dominguez-Meijide A; Labandeira-Garcia JL
    Exp Neurol; 2014 Nov; 261():720-32. PubMed ID: 25160895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta).
    Shughrue PJ
    Exp Neurol; 2004 Dec; 190(2):468-77. PubMed ID: 15530885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
    Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
    Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson's disease.
    Galuppo M; Iori R; De Nicola GR; Bramanti P; Mazzon E
    Bioorg Med Chem; 2013 Sep; 21(17):5532-47. PubMed ID: 23810671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
    Zhao Y; Zhang Q; Xi J; Xiao B; Li Y; Ma C
    Int J Clin Exp Pathol; 2015; 8(3):2354-64. PubMed ID: 26045742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease.
    Rodriguez-Perez AI; Valenzuela R; Villar-Cheda B; Guerra MJ; Lanciego JL; Labandeira-Garcia JL
    Exp Neurol; 2010 Aug; 224(2):517-26. PubMed ID: 20580712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
    Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.